2 hours ago
1
- Celcuity (NASDAQ:CELC) is up ~47% in Monday morning trading after reporting strong results from a cohort in a phase 3 trial of its breast cancer candidate gedatolisib.
- Patients with PIK3CA wild-type gene and HR+/HER- breast cancer who took gedatolisib along with
English (US) ·